BRIEF published on 11/04/2024 at 10:16, 17 days 3 hours ago Sartorius Stedim Biotech Statement on Shares and Voting Rights Share Capital Voting Rights Actions AMF Sartorius Stedim
PRESS RELEASE published on 11/04/2024 at 10:11, 17 days 3 hours ago Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL Sartorius Stedim Biotech SA declares the number of shares and voting rights in the issued capital. Total shares: 97,330,405. Total voting rights: 165,567,396 Voting Rights Shares Sartorius Stedim Biotech Issued Capital French Regulatory News
BRIEF published on 10/17/2024 at 07:07, 1 month 4 days ago Sartorius Stedim Biotech: Unaudited results for the first nine months of 2024 Financial Results Sartorius Stedim Biotech Outlook 2024 Advanced Therapies Turnover
PRESS RELEASE published on 10/17/2024 at 07:02, 1 month 4 days ago Sartorius Stedim Biotech publishes unaudited results for the first nine months of 2024 Sartorius Stedim Biotech posts unaudited 9-month results for 2024, confirming outlook. Sales revenue 2,029 million euros, EBITDA 565 million euros, strong consumables demand EBITDA Sartorius Stedim Biotech Sales Revenue 9-month Figures Consumables
BRIEF published on 10/01/2024 at 11:19, 1 month 20 days ago Statement on the number of shares and voting rights at Sartorius Stedim Biotech Share Capital Voting Rights Actions Sartorius Stedim Biotech Regulatory
PRESS RELEASE published on 10/01/2024 at 11:15, 1 month 20 days ago Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL Press release regarding the declaration of the number of shares and voting rights of Sartorius Stedim Biotech S.A. in France Voting Rights Capital Shares Sartorius Stedim Biotech France
PRESS RELEASE published on 10/01/2024 at 11:14, 1 month 20 days ago Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL Sartorius Stedim Biotech SA declares number of shares and voting rights making up the issued capital. Details according to French regulations Voting Rights Shares French Regulations Sartorius Stedim Biotech Issued Capital
BRIEF published on 09/03/2024 at 10:20, 2 months 18 days ago Sartorius Stedim Biotech SA Announces Number of Shares and Voting Rights Voting Rights Shares Issued Capital Regulatory News Sartorius Stedim
PRESS RELEASE published on 09/03/2024 at 10:15, 2 months 18 days ago Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL Press release regarding the declaration of the number of shares and voting rights at Sartorius Stedim Biotech S.A. in France Voting Rights Déclaration Shares Sartorius Stedim Biotech France
PRESS RELEASE published on 09/03/2024 at 10:15, 2 months 18 days ago Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL Sartorius Stedim Biotech SA declares the number of shares and voting rights in the issued capital. Total shares: 97,330,405. Total voting rights: 165,568,221 Voting Rights Shares Sartorius Stedim Biotech Issued Capital Announcement
Published on 11/21/2024 at 13:00, 26 minutes ago Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 26 minutes ago Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 26 minutes ago Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography
Published on 11/21/2024 at 13:00, 26 minutes ago Nextech3D.ai Spin-Out Rebrands as FOTOgpt.ai to Usher in a New Era of AI-Powered Photography
Published on 11/21/2024 at 13:00, 26 minutes ago Clean Air Metals Announces Positive Results from Innovative Seismic Survey at the Escape Deposit Down-Plunge Extension
Published on 11/21/2024 at 12:35, 50 minutes ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 11 minutes ago Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 06:58, 6 hours 28 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 6 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 19 hours 41 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 19 hours 41 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 5 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
